Skip to main content
. 2016 Dec 16;8(6):9251–9266. doi: 10.18632/oncotarget.14002

Figure 5. Effects of LY3009120 on CRC xenografts.

Figure 5

(A) Colo 205 (BRAFmut), HT-29 (BRAFmut), HCT 116 (KRASmut) or Colo 320HSR (KRASWT/BRAFWT) CRC lines were implanted subcutaneously in the right flank of nude rats and the animals were treated orally with either vehicle (•) or LY3009120 (Colo 205: 20 mg/kg; HCT 116: 30 mg/kg; HT-29: 20 mg/kg; Colo 320HSR 30mg/kg) (○) twice daily and were monitored for tumor size. Arrow: Day of dosing initiation. Blue line: Duration of dosing. p < 0.01 (**); p < 0.001 (***); n.s. (not significant). (B) HT-29 (BRAFmut) xenograft model treated with either vehicle or LY3009120 (20 mg/kg BID) or (C) Colo 320HSR xenograft model treated with either vehicle or LY3009120 (30 mg/kg BID) were assessed by Western blot for levels of phospho- and total MEK1/2, ERK1/2 and tubulin as indicated.